WASHINGTON (Reuters) - The most commonly used tool for detecting prostate cancer, routine PSA screening, has become “a hugely expensive public health disaster,” its discoverer said on Wednesday.
WASHINGTON (Reuters) - The most commonly used tool for detecting prostate cancer, routine PSA screening, has become “a hugely expensive public health disaster,” its discoverer said on Wednesday.
